(Q38133178)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23994536%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23994536%20AND%20SRC:MED&resulttype=core&format=json

evasion of host immune response

8 March 2020

main subject

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23994536%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Pablo Conesa-Zamora

series ordinal

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

29 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23994536%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23994536%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23994536%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23994536%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

480-488

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23994536%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Immune evasion in human papillomavirus-associated cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Molecular biology of human papillomavirus infection and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Close encounters of different kinds: dendritic cells and NK cells take centre stage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Identification of key amino acid residues that determine the ability of high risk HPV16-E7 to dysregulate major histocompatibility complex class I expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Tumor-specific regulatory T cells in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Langerhans' cells and smoking in intraepithelial neoplasia of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Human leukocyte antigen class II and cervical cancer risk: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Genetic variants in TAP are associated with high-grade cervical neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Interleukin-10 gene (IL10) polymorphisms and human papillomavirus clearance among immunosuppressed adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Association of polymorphism in FcGR3A gene and progression of low-grade precursor lesions of cervical carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Impact of Toll-like receptors [TLR] 2 (-196 to -174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Measuring serum antibody to human papillomavirus following infection or vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

New Approaches to Immunotherapy for HPV Associated Cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Adjuvants for cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Immunotherapy for cervical cancer: Research status and clinical potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Association between toll-like receptor expression and human papillomavirus type 16 persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Treatment of vulvar intraepithelial neoplasia with topical imiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Molecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

siRNA and shRNA as anticancer agents in a cervical cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.08.025

10.1016/J.YGYNO.2013.08.025

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23994536%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference